Inari Medical, Inc. (NASDAQ:NARI) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund raised its position in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 10.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 311,410 shares of the company's stock after purchasing an additional 29,983 shares during the quarter. New York State Common Retirement Fund owned 0.54% of Inari Medical worth $20,217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Inari Medical by 99.7% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 45,621 shares of the company's stock valued at $2,962,000 after acquiring an additional 22,780 shares during the last quarter. Bamco Inc. NY boosted its holdings in shares of Inari Medical by 18.2% during the 3rd quarter. Bamco Inc. NY now owns 557,937 shares of the company's stock valued at $36,489,000 after acquiring an additional 86,000 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Inari Medical in the third quarter worth approximately $2,564,000. Fiera Capital Corp boosted its holdings in shares of Inari Medical by 63.4% in the third quarter. Fiera Capital Corp now owns 560,756 shares of the company's stock worth $36,673,000 after buying an additional 217,606 shares during the last quarter. Finally, Asset Management One Co. Ltd. boosted its holdings in shares of Inari Medical by 19.5% in the third quarter. Asset Management One Co. Ltd. now owns 47,390 shares of the company's stock worth $3,099,000 after buying an additional 7,720 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NARI has been the topic of a number of research reports. Piper Sandler downgraded shares of Inari Medical from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $85.00 to $55.00 in a report on Thursday, February 29th. Needham & Company LLC reissued a "buy" rating and issued a $72.00 price objective on shares of Inari Medical in a report on Wednesday, March 6th. Canaccord Genuity Group restated a "buy" rating and set a $75.00 target price on shares of Inari Medical in a research note on Friday, April 12th. Finally, Truist Financial decreased their target price on shares of Inari Medical from $61.00 to $52.00 and set a "hold" rating on the stock in a research note on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Inari Medical has an average rating of "Moderate Buy" and a consensus target price of $73.71.

Insider Buying and Selling

In related news, CFO Mitch C. Hill sold 6,000 shares of the business's stock in a transaction on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the sale, the chief financial officer now owns 181,294 shares in the company, valued at $7,425,802.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Inari Medical news, Director William Hoffman sold 1,451 shares of Inari Medical stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total transaction of $58,040.00. Following the completion of the transaction, the director now directly owns 999,782 shares of the company's stock, valued at $39,991,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the transaction, the chief financial officer now directly owns 181,294 shares of the company's stock, valued at $7,425,802.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,451 shares of company stock worth $1,949,000. Insiders own 10.60% of the company's stock.

Inari Medical Stock Performance

Shares of Inari Medical stock traded up $0.35 on Friday, hitting $38.42. 1,115,381 shares of the company traded hands, compared to its average volume of 981,529. The stock has a market capitalization of $2.23 billion, a P/E ratio of -1,280.67 and a beta of 0.84. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $71.85. The business has a 50-day simple moving average of $44.86 and a 200 day simple moving average of $54.24.

Inari Medical (NASDAQ:NARI - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.09). The company had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The company's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.11) EPS. Research analysts expect that Inari Medical, Inc. will post -0.25 earnings per share for the current year.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.